Fibroblast Growth Factor (FGF-23) in Pre-Dialytic Chronic Kidney Disease Patients



  • Sandhya Sivaraman

    Ph.D. Student, Sir H. N. Medical Research Society, Sir H. N. Hospital and Research Centre, Court House, L. T. Road, Mumbai 400 002, India.

  • Arun Halankar

    Consultant Nephrologist, Sir H. N. Reliance Foundation Hospital and Research Centre, Raja Rammohan Roy Road, Mumbai 400 004, India.

  • Kavita Shalia

    Sr. Scientist, Sir H. N. Medical Research Society, Court House, L. T. Road, Mumbai 400 002, India.



Objective: Fibroblast Growth Factor (FGF-23); a Phosphaturic peptide hormone, has recently been identified as a regulator of calcium-Phosphorus metabolism. Aim of the present study was to analyse FGF-23 in addition to the conventional indicators of bone metabolism in pre-dialytic CKD patients. METHODS: Pre-dialytic CKD Stage 1 and 2 (N=10) and Stage 3 and 4 (N=14) patients were observed for different indicators of bone metabolism including Total, intact (active) and C-terminal FGF-23 (inactive) levels at recruitment as compared to age matched controls (N=14) and as compared to their profile at six month. RESULTS: In CKD stage (1-4) patients, phosphorus levels were within normal range but showed negative correlation with eGFR (Linear correlation (r) = -0.467, p=0.021) and positive correlation with C-terminal FGF-23 levels (spearman correlation (rs) = 0.464, p=0.022). As compared to the controls, in stage 1 and 2 Total, intact and C-terminal FGF-23 increased significantly (p=0.001) by 16.4, 2.1 and 19.2 fold and in stage 3 and 4 by 28.6, 2.4 and 32.3 fold respectively. Thus, increase in the C-terminal by intact-FGF-23 in control, CKD stage 1 and 2 and CKD stage 3 and 4 were 4.5, 41.8 and 60.6 fold respectively. These patients were on regular calcium and vitamin D treatment. Follow-up study at six month did not show any change in FGF-23 levels. CONCLUSION: In the absence of hyperphosphatemia at early stages of CKD, FGF-23 levels increased with declining renal function. Increase in C-terminal FGF-23 over intact-FGF23 levels might greatly advance understanding of mineral bone disease in CKD


Download data is not yet available.


Metrics Loading …



Modi G, Jha V. Incidence of ESRD in India. Kidney Int. 2011; 79(5): 573.

Locatelli F, Cannata?And

Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow, GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J of the Am Soc of Nephrol. 2004; 15(8): 2208-18.

Schmitt C P, Odenwald T, Ritz E. Calcium, calcium regulatory hormones, and calcimimetics: impact on cardiovascular mortality. Journal of the Am Soc of Nephrol.2006; 17(4 suppl 2): S78-S80.

Portale AA, Booth BE, Tsai HC, Morris Jr RC. Reduced plasma concentration of 1, 25-dihydroxyvitamin D in children with moderate renal insufficiency. Kidney Int. 1982; 21(4): 627-32.

Wilson L, Felsenfeld A, Drezner MK, Llach, F. Altered divalent ion metabolism in early renal failure: Role of 1, 25 (OH) 2D. Kidney Int. 1985; 27(565-573): 15.

Hsu CY, Chertow GM. Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency. Nephrol Dial Transplant. 2002; 17(8): 1419

Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care. 2008; 35(2):329-44.

Tomasello S. Secondary hyperparathyroidism and chronic kidney disease. Diabetes Spectrum. 2008; 21(1): 19-25.

White KE, Evans WE, O’Riordan JL, Speer MC, Econs MJ, Lorenz-Depiereux B, et al. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF-23. Nature Genet. 2000; 26(3): 345-8.

Saito H, Kusano K, Kinosaki M, Ito H, Hirata M, Segawa H, et al. Human fibroblast growth factor-23 mutants suppress Na-dependent phosphate cotransport activity and 1 alpha, 25-dihydroxyvitamin D3 production. J Biol Chem. 2003; 278(4): 2206-11.

Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004; 19(3): 429-35.

Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int. 2004; 65(1): 1-14.

Fukagawa M, Kazama JJ. With or without the kidney: the role of FGF-23 in CKD. Nephrol Dial Transplant. 2005; 20(7): 1295-98.

Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J of Biol Chem. 2006; 281(10): 6120-23.

Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 2002; 143(8): 3179-82.

Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant. 2010; 25(12): 3983-9.


Prasad N, Jaiswal A, Kumar S, Nath M, Yadav B, Agarwal V. Fibroblast growth factor 23 and intact parathormone in post-transplant period on longitudinal follow-up. Nephrol Dial Transplant. 2015; 30(suppl 3): iii362.

Eknoyan G, Levin NW. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification-Foreword. Am J Kidney Dis. 2002; 39(2): S14-S26.

Devaraj S, Duncan-Staley C, Jialal I. Evaluation of a method for fibroblast growth factor-23: a novel biomarker of adverse outcomes in patients with renal disease. Metab Syndr Relat Disord. 2010; 8(6): 477-82.

Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005; 16(7): 2205-15.

Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007; 71(1): 31-38.

Hoenderop JG, Bindels RJ. Is vitamin D indispensable for Ca2+ homeostasis: lessons from knockout mouse models? Nephroly Dial Transplan.t 2005; 20(5): 864-67.

Isakova T, Guti

Shigematsu T, Kazama JJ, Yamashita T, Fukumoto S, Hosoya T, Gejyo, F, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am j of kid Dis. 2004; 44(2): 250-6.

Evenepoel P, Meijers B, Viaene L, Bammens B, Claes K, Kuypers D, et al. Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clin J of the Am Soc of Nephrol. 2010; 5(7): 1268-76.

Goetz R, Nakada Y, Hu MC, Kurosu H, Wang L, Nakatani T, et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A. 2010; 107(1): 407-12.




How to Cite

Sivaraman S, Halankar A, Shalia K. . Int Jour of Biomed Res [Internet]. 2016 Sep. 30 [cited 2022 Jun. 17];7(9):663-70. Available from:



Original Research Articles

Dr. Jun Ren is a dedicated and experienced registered dietitian and nutritionist who is committed to helping people achieve their health goals through personalized nutrition plans. With a passion for promoting healthy eating habits and preventing chronic diseases, Dr. Ren has been able to assist numerous clients in improving their overall quality of life.

Leave a Comment